| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.002 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.74 | 0.003 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |